Abstract
Objective
To observe the safety and efficacy of Colistimethate sodium in children infected with gram-negative bacteria, susceptible only to colistimethate sodium.
Methods
This prospective observational study done over 2 years observed children who received colistin for >48 h, for renal failure as defined by p-RIFLE criteria.
Results
Out of 68 children, 52 (76.5%) survived. There were three children with evidence of acute kidney injury and none had neurotoxicity. Serum creatinine significantly decreased at 48 h and at end of treatment, from that at beginning of therapy (P=0.007).
Conclusion
Colistimethate sodium is effective against carbapenem-resistant Gram-negative bacteria, and is safe in children.
Article PDF
Similar content being viewed by others
References
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt FA, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597–602.
Harish BN, Menezes GA, Shekatkar S, Parija SC. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae from blood culture. J Med Microbiol. 2007;56:999–1000.
Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449–65.
Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R, Gerber JS, et al. The use of intravenous colistimethate sodium among children in the United States: Results from a multicenter case series. Pediatr Infect Dis J. 2012;32:17–22.
Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistimethate sodium use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents. 2009;33:e1–13.
Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistimethate sodium administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867–74.
Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Pediatr Infect Dis J. 2011;30:218–21.
Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028–35.
Libório AB, Branco KMPC, Bezerra CT. Acute kidney injury in neonates: From urine output to new biomarkers. Biomed Res Int. 2014. http://dx.doi.org/10.1155/2014/601568.
Kapoor K, Jajoo M, Dublish S, Dabas V, Gupta S, Manchanda V. Intravenou colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. Pediatr Crit Care Med. 2013;14:e268–72.
Rosanova M, Epelbaum C, Noman A, Villasboas M, Alvarez, V, Berberian G, et al. Use of colistimethate sodium in a pediatric burn unit in Argentina. J Burn Care Res. 2009; 30:612–5.
Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistimethate sodium) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J. 2009; 28:123–7.
Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistimethate sodium for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. J Burn Care Res. 2007; 28:421–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kumar, P.P., Giri, S.R., Shaikh, F.A.R. et al. Safety and efficacy of intravenous colistin in children. Indian Pediatr 52, 129–130 (2015). https://doi.org/10.1007/s13312-015-0586-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-015-0586-1